|
Market Closed -
Sao Paulo
23:50:46 20/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 65.52 BRL | +1.08% |
|
+5.30% | +14.29% |
| 10-19 | Gilead Sciences, Inc. Presents New Findings From Its HIV And Antiviral Research And Development Programs At IDWeek 2026 | CI |
| 10-19 | Gilead's pill succeeds in mid-stage bowel disease trial | RE |
| Market Cap | 190B 952B 169B 157B 142B 267B 17,980B 271B 1,879B 738B 9,409B 712B 697B 30,017B | P/E 2026 * |
-44.7x | P/E 2027 * | 19x |
|---|---|---|---|---|---|
| Enterprise Value | 211B 1,059B 188B 174B 158B 297B 19,995B 301B 2,089B 821B 10,464B 792B 775B 33,381B | EV / Sales 2026 * |
6.87x | EV / Sales 2027 * | 6.19x |
| Free-Float |
99.89% | Yield 2026 * |
2.15% | Yield 2027 * | 2.19% |
Last Transcript: Gilead Sciences, Inc.
| 1 day | +1.08% | ||
| 1 week | +5.30% | ||
| Current month | -0.64% | ||
| 1 month | +1.88% | ||
| 3 months | +15.67% | ||
| 6 months | +23.28% | ||
| Current year | +14.29% |
| 1 week | 63.84 |  | 67.38 |
| 1 month | 59.28 | | 67.38 |
| Current year | 52.08 | | 67.38 |
| 1 year | 52.08 | | 67.38 |
| 3 years | 27.26 | | 67.38 |
| 5 years | 22.04 | | 67.38 |
| 10 years | 17.05 | | 67.38 |
| Manager | Title | Age | Since |
|---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 61 | 01/03/2019 |
Andrew Dickinson
DFI | Director of Finance/CFO | 56 | 01/11/2019 |
Keeley Wettan
CMP | Compliance Officer | - | 18/12/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kelly Kramer
BRD | Director/Board Member | 58 | 19/08/2016 |
| Director/Board Member | 73 | 01/01/2018 | |
Harish Manwani
BRD | Director/Board Member | 72 | 09/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.08% | +5.30% | - | - | 190B | |
| +3.49% | +10.04% | +58.68% | +119.56% | 1,106B | |
| +2.19% | +4.32% | +33.88% | +69.52% | 612B | |
| +2.26% | +5.37% | +24.57% | +97.69% | 500B | |
| +2.58% | +8.31% | +37.43% | +63.51% | 367B | |
| +3.25% | +4.45% | +71.80% | +44.44% | 354B | |
| +1.85% | +5.45% | +21.38% | +49.26% | 286B | |
| +1.76% | +4.92% | +0.48% | +20.31% | 256B | |
| +3.29% | +6.32% | +44.71% | +57.43% | 230B | |
| +2.25% | +5.81% | +27.13% | +101.17% | 190B | |
| Average | +2.51% | +2.13% | +35.56% | +69.21% | 433.35B | |
| Weighted average by Cap. | +2.85% | +2.30% | +40.70% | +80.58% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 30.73B 154B 27.35B 25.35B 22.97B 43.17B 2,911B 43.89B 304B 119B 1,523B 115B 113B 4,860B | 32.84B 165B 29.23B 27.09B 24.55B 46.13B 3,111B 46.9B 325B 128B 1,628B 123B 121B 5,193B |
| Net income | -4.26B -21.36B -3.79B -3.51B -3.18B -5.98B -403B -6.08B -42.13B -16.55B -211B -15.97B -15.64B -673B | 10.27B 51.52B 9.14B 8.47B 7.68B 14.43B 973B 14.67B 102B 39.93B 509B 38.52B 37.72B 1,624B |
| Net Debt | 21.27B 107B 18.93B 17.55B 15.9B 29.88B 2,015B 30.38B 211B 82.72B 1,055B 79.79B 78.14B 3,364B | 13.62B 68.33B 12.12B 11.24B 10.18B 19.13B 1,290B 19.45B 135B 52.96B 675B 51.09B 50.03B 2,154B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/10/26 | R$65.52 | +1.08% | 5 |
| 19/10/26 | R$64.82 | -1.50% | 2 |
| 16/10/26 | R$65.81 | -1.98% | 1,782 |
| 15/10/26 | R$67.14 | +4.22% | 5 |
| 14/10/26 | R$64.42 | +3.54% | 221 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GILD Stock
- GILD34 Stock
Select your edition
All financial news and data tailored to specific country editions
